Drug Trial Radar · NCT03247530
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
Last checked: Nov 20, 2026Latest source record: Jul 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
477
Actual
Start
Oct 20, 2017
Primary completion
Sep 12, 2018
Study completion Sep 12, 2018
Sponsor
- Lead sponsor
- Supernus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of low doses of SPN-812 in children 6-11 years of age diagnosed with ADHD.
Conditions
- ADHD
Interventions
PlaceboDrug
Placebo was administered once daily
100mg SPN-812Drug
100mg SPN-812 was administered once daily and compared to placebo
200mg SPN-812Drug
200mg SPN-812 was administered once daily and compared to placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale, 5th Edition (ADHD-RS-5)Time frame: Baseline and Week 6 (End of Study)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Harmonex Neuroscience Research
Dothan, Alabama
Indago Research & Health Center, Inc.
Hialeah, Florida
Advanced Clinical Research
Meridian, Idaho
Finger Lakes Clinical Research
Rochester, New York
Houston Clinical Trials
Houston, Texas
Family Psychiatry of the Woodlands
The Woodlands, Texas
Aspen Clinical Research
Orem, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.